Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan Laboratories to Enter Japan's Generic Drug Market (Japan)

This article was originally published in PharmAsia News

Executive Summary

Mylan Laboratories Inc., the number three generic drug producer in the world, is working to break into Japan's generic market. Recently Mylan bought out the generic end of Germany's Merck KGaA. The Merck deal gave Mylan control of subsidiaries selling generics in 90 countries around the world. Among these companies is the Japan-based Merck Seiyaku Ltd. Mylan plans to work with Seiyaku to expand its generic business across the country, especially production of slow-release formulas, Mylan's specialty. Seiyaku will also team up with India's Matric Laboratories Ltd., which is also an affiliate of Mylan. The two companies will work together to expand Matrix's active pharmaceutical ingredient business in Japan. (Click here for more

You may also be interested in...



India Generic Drug Maker Matrix Increases Stake in China's Mchem

NEW DELHI - Hyderabad, India-based Matrix Laboratories has increased its stake in China-based Mchem group to 97 percent from 60 percent for an undisclosed amount, Matrix said

Warning Letter Close-Outs – October 2020

The US FDA issued only one device-related close-out letter in October.

Compounding Pharmacies Sue FDA For Conflating Out-Of-State Dispensing And Distribution In MOU

Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.

UsernamePublicRestriction

Register

ID1129947

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel